NCT00298506 is a NA clinical trial of Multitherapy in Lupus Nephritis, sponsored by Nanjing University School of Medicine.

Who is sponsoring NCT00298506?

NCT00298506 is sponsored by Nanjing University School of Medicine.

What drugs are being tested in NCT00298506?

Interventions in NCT00298506: Multitherapy.

What condition does NCT00298506 study?

NCT00298506 studies Lupus Nephritis.

Is NCT00298506 still recruiting?

NCT00298506 is currently completed. Last updated 28 September 2011.

Last reviewed 2011-09-28 · How we verify

NCT00298506

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open, Prospective Study to Assess the Efficacy and Safety of FK506 Combined MMF in the Treatment of Class III，IV，V + IV or V + III Lupus Nephritis

Completed NA Last updated 28 September 2011

What this trial tests

NA trial testing Multitherapy in Lupus Nephritis in 120 participants. Completed in 1 June 2009.

Timeline

1 September 2005

Primary endpoint
1 December 2008

1 June 2009

Quick facts

Lead sponsor	Nanjing University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 September 2005
Primary completion	1 December 2008
Estimated completion	1 June 2009
Sites	2 locations across China

Drugs / interventions tested

Multitherapy — full drug profile →

Conditions studied

Lupus Nephritis — all drugs for Lupus Nephritis →

Sponsor

Nanjing University School of Medicine

Who can join

Adults 12 to 50, female only, with Lupus Nephritis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To assess the efficacy of FK506 combined with MMF versus intravenous CTX pulses in treatment of LN
Time frame: 18 months

Sponsor's own description

This is an open, prospective study to assess the efficacy and safety of Tacrolimus (FK506) combined with MMF in the treatment of class III, IV, V + IV or V + III lupus nephritis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Successful treatment of class V+IV lupus nephritis with multitarget therapy.
Bao H, Liu ZH, Xie HL, Hu WX, et al · · 2008 · cited 193× · PMID 18596121 · DOI 10.1681/asn.2007121272
Efficacy and safety of biologics, multitarget therapy, and standard therapy for lupus nephritis: a systematic review and network meta-analysis.
Tian GQ, Li ZQ. · · 2024 · cited 6× · PMID 39212247 · DOI 10.1080/0886022x.2024.2395451
Efficacy and safety of calcineurin inhibitor therapy in lupus nephritis: a systematic review and network meta-analysis.
Wu Y, Cai W, Yao Y, Zhang J. · · 2025 · PMID 41550942 · DOI 10.3389/fimmu.2025.1670134

Verify or expand the search:

Other recruiting trials for Lupus Nephritis

Currently open trials in the same condition.

NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
NCT07109986 — UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis · Phase 1 · recruiting
NCT07053891 — LUPKYNIS Drug-use Results Survey · recruiting
NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
NCT06711887 — Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants · Phase 3 · recruiting

Other Nanjing University School of Medicine trials

Trials by the same sponsor.

NCT06285279 — The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases · Phase 1 · recruiting
NCT06226896 — Effects of Dapagliflozin on Progression of Alport Syndrome · active not recruiting
NCT05863936 — Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis · Phase 3 · unknown
NCT06376214 — Daratumumab for Patients With Light Chain Amyloidosis · NA · recruiting
NCT04507945 — Stablishment of Prevention and Treatment System for Intestinal Dysfunction · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00298506 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing University School of Medicine
Last refreshed: 28 September 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00298506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing